← Back to Search

Unknown

INL1 for Heart Failure (TRACER-HF Trial)

Phase 2
Waitlist Available
Research Sponsored by Innolife Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 12 weeks
Awards & highlights

TRACER-HF Trial Summary

This trial will test a new drug, INL1, to see if it can help people with heart failure. Patients will be given either INL1 or a placebo twice a day for 12 weeks to see if there is a difference.

Eligible Conditions
  • Decreased Ejection Fraction
  • Heart Failure

TRACER-HF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportional change in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
Secondary outcome measures
Change in 6 minute walk distance
Change in Inferior Vena Cava (IVC) Diameter
Change in Left Atrial Volume (LAV)
+19 more

TRACER-HF Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: INL1 50mg BIDExperimental Treatment1 Intervention
INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
Group II: INL1 300 mg BIDExperimental Treatment1 Intervention
INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
Group III: INL1 150 mg BIDExperimental Treatment1 Intervention
INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
Group IV: PlaceboPlacebo Group1 Intervention
Placebo dose to be given twice daily using 3 placebo capsules at each dose

Find a Location

Who is running the clinical trial?

Innolife Co., Ltd.Lead Sponsor
Michael Chen, MDStudy ChairInnolife Co., Ltd.
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can elderly citizens participate in this experiment?

"The age limit for this particular clinical trial is 75 years old, with a minimum age of 18."

Answered by AI

Are recruitment efforts for this study ongoing?

"This trial is recruiting patients according to clinicaltrials.gov. The listing was first posted on 1/20/2020 and the most recent edit was made on 3/28/2022."

Answered by AI

Who meets the screening criteria for this research project?

"The ideal candidate for this study should be suffering from heart failure and between the ages of 18-75. Around 200 people will be accepted into the trial."

Answered by AI

What is the mortality rate for patients with INL1?

"While there is some evidence to support the safety of INL1, it has not been proven effective yet. Consequently, our team at Power rated it a 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
2020. "Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03875183.
~38 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top